B. Thompson, V. Ranieri, and S. Finfer, Statistical analysis plan of PROWESS SHOCK study, Intensive Care Medicine, vol.11, issue.11, pp.1972-1975, 2010.
DOI : 10.1007/s00134-010-1977-3

V. Ranieri, B. Thompson, and S. Finfer, Unblinding plan of PROWESS-SHOCK trial, Intensive Care Medicine, vol.34, issue.8, pp.1384-1389, 2011.
DOI : 10.1007/s00134-011-2272-7

E. Ely, P. Laterre, and D. Angus, Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis, Critical Care Medicine, vol.31, issue.1, pp.12-21, 2003.
DOI : 10.1097/00003246-200301000-00002

G. Bernard, W. Macias, D. Joyce, M. Williams, J. Bailey et al., Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis, Critical Care, vol.7, issue.2, pp.155-63, 2003.
DOI : 10.1186/cc2167

J. Dhainaut, P. Laterre, and J. Janes, Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial, Intensive Care Medicine, vol.1, issue.6, pp.894-903, 2003.
DOI : 10.1007/s00134-003-1731-1

J. Vincent, D. Angus, and A. Artigas, Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial*, Critical Care Medicine, vol.31, issue.3, pp.834-874, 2003.
DOI : 10.1097/01.CCM.0000051515.56179.E1

D. Fry, G. Beilman, and S. Johnson, Safety of Drotrecogin Alfa (Activated) in Surgical Patients with Severe Sepsis, Surgical Infections, vol.5, issue.3, pp.253-262, 2004.
DOI : 10.1089/sur.2004.5.253

M. Levi, M. Levy, and M. Williams, Prophylactic Heparin in Patients with Severe Sepsis Treated with Drotrecogin Alfa (Activated), American Journal of Respiratory and Critical Care Medicine, vol.176, issue.5, pp.483-90, 2007.
DOI : 10.1164/rccm.200612-1803OC

P. Barie, L. Hydo, J. Shou, S. Eachempati, J. Russell et al., Efficacy of therapy with recombinant human activated protein C of critically ill surgical patients with infection complicated by septic shock and multiple organ dysfunction syndrome Vasopressin versus norepinephrine infusion in patients with septic shock, Surg Infect (Larchmt) N Engl J Med, vol.12358, issue.19, pp.443-9877, 2008.

J. Escarce, M. Kelley, T. Koperna, D. Semmler, and M. F. , Admission source to the medical intensive care unit predicts hospital death independent of APACHE II score Risk stratification in emergency surgical patients: is the APACHE II score a reliable marker of physiological impairment?, Maharaj R. Vasopressors and the search for the optimal trial design, pp.2389-9455, 1990.

D. Backer, D. Biston, P. Devriendt, and J. , Comparison of dopamine and norepinephrine in the treatment of shock Hydrocortisone therapy for patients with septic shock, N Engl J Med N Engl J Med, vol.362358, pp.779-89111, 2008.

S. Rao, D. Schoenfeld, J. Dhainaut, S. Yan, and D. Joyce, Survival methods Treatment effects of drotrecogin alfa (activated ) in patients with severe sepsis with or without overt disseminated intravascular coagulation, Circulation J Thromb Haemost, vol.1152, issue.26, pp.109-131924, 2004.

W. Macias, D. Nelson, A. Shorr, G. Bernard, and J. Dhainaut, Severe protein C deficiency predicts early death in severe sepsis Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome Epidemiology of severe sepsis in the United States: analysis of incidence, outcome , and associated costs of care, Crit Care Med Crit Care Crit Care Med, vol.321029, pp.1303-1313, 2001.

G. Martin, D. Mannino, S. Eaton, M. Moss, J. Vincent et al., The epidemiology of sepsis in the United States from Sepsis in European intensive care units: results of the SOAP study Australasian Resuscitation in Sepsis Evaluation (ARISE) Investigators. The outcome of patients with sepsis and septic shock presenting to emergency departments in Australia and New Zealand al. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis, N Engl J Med Crit Care Med Crit Care Resusc Levy MM Crit Care Med, vol.348349, issue.38, pp.1546-54344, 1979.

T. Rice, A. Wheeler, and G. Bernard, double-blind, placebocontrolled trial of TAK-242 for the treatment of severe sepsis Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis The effect of drotrecogin alfa (activated ) on long-term survival after severe sepsis Food and Drug Administration. Voluntary market withdrawal of Xigris [drotrecogin alfa (activated)] due to failure to show a survival benefit, Crit Care Med Crit Care Med [Erratum, Crit Care Med Crit Care Med, vol.38383832, issue.37, pp.1685-9472, 2004.

S. , 2. Anniversary, . To, and . Nejm, Join your peers in posting an anniversary message and read the collected messages at the NEJM 200th Anniversary website, NEJM200.NEJM.org. We look forward to hearing from you